158 related articles for article (PubMed ID: 1836706)
1. Comparative antitumor activity of 5-fluorouracil and its prodrugs in combination with hyperthermia in vitro.
Shiiki S; Fuchimoto S; Iwagaki H; Akazai Y; Matsubara N; Watanabe T; Orita K
Acta Med Okayama; 1991 Oct; 45(5):339-45. PubMed ID: 1836706
[TBL] [Abstract][Full Text] [Related]
2. Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine.
Ooi A; Ohkubo T; Higashigawa M; Kawasaki H; Kakito H; Kagawa Y; Kojima M; Sakurai M
Biol Pharm Bull; 2001 Nov; 24(11):1329-31. PubMed ID: 11725974
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of antitumor effects of 1-hexylcarbamoyl-5-fluorouracil combined with hyperthermia on Ehrlich ascites tumor in vivo and Nakahara-Fukuoka sarcoma cell in vitro.
Tsumura M; Yoshiga K; Takada K
Cancer Res; 1988 Jul; 48(14):3977-80. PubMed ID: 3383192
[TBL] [Abstract][Full Text] [Related]
4. [Human colorectal carcinoma is more sensitive to HCFU than 5-FU and tegafur in in vitro and in vivo drug sensitivity tests].
Kusumoto T; Maehara Y; Anai H; Kusumoto H; Miyamoto K; Fukuchi K; Sugimachi K
Gan To Kagaku Ryoho; 1988 Feb; 15(2):257-61. PubMed ID: 3124767
[TBL] [Abstract][Full Text] [Related]
5. 1-Hexylcarbamoyl-5-fluorouracil is more cytostatic than 5-fluorouracil against human tumors in vitro.
Maehara Y; Kusumoto H; Anai H; Kusumoto T; Hiramoto Y; Sugimachi K
Eur J Cancer Clin Oncol; 1987 Oct; 23(10):1511-5. PubMed ID: 3678315
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermia enhances the in vitro activity of 1-hexylcarbamoyl-5-fluorouracil compared to that of 5-fluorouracil.
Kusumoto T; Maehara Y; Sakaguchi Y; Sugimachi K
Eur J Cancer Clin Oncol; 1989 Mar; 25(3):477-81. PubMed ID: 2703002
[TBL] [Abstract][Full Text] [Related]
7. Comparative antitumor activity and intestinal toxicity of 5'-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5'-deoxy-5-fluorocytidine.
Ninomiya Y; Miwa M; Eda H; Sahara H; Fujimoto K; Ishida M; Umeda I; Yokose K; Ishitsuka H
Jpn J Cancer Res; 1990 Feb; 81(2):188-95. PubMed ID: 2139643
[TBL] [Abstract][Full Text] [Related]
8. Effects of thermochemotherapy [1-hexylcarbamoyl-5-fluorouracil (HCFU) combined with hyperthermia]: a basic study on the most effective timing and sequence in vivo.
Sakurai K; Yoshiga K; Tsumura M; Takada K
Anticancer Res; 1996; 16(5A):2729-33. PubMed ID: 8917379
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo.
Takeda Y; Yoshizaki I; Nonaka Y; Yanagie H; Matsuzawa A; Eriguchi M
Anticancer Drugs; 2001 Sep; 12(8):691-8. PubMed ID: 11604557
[TBL] [Abstract][Full Text] [Related]
10. [Enhancement effect of interferon gamma on the sensitivity of RT4 bladder cancer cells to 5'-deoxy-5-fluorouridine,and 5-fluorouracil through up-regulation of PD-ECGF/TP].
Li G; Yan CY; Wen DG; Ding Q; Zhang YF
Ai Zheng; 2004 Aug; 23(8):929-32. PubMed ID: 15301717
[TBL] [Abstract][Full Text] [Related]
11. Comparative studies on the immunosuppressive effect among 5'-deoxy-5-fluorouridine, ftorafur, and 5-fluorouracil.
Ohta Y; Sueki K; Kitta K; Takemoto K; Ishitsuka H; Yagi Y
Gan; 1980 Apr; 71(2):190-6. PubMed ID: 6451468
[TBL] [Abstract][Full Text] [Related]
12. Differential selectivity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in cultured human B lymphocytes and mouse L1210 leukemia.
Au JL; Rustum YM; Minowada J; Srivastava BI
Biochem Pharmacol; 1983 Feb; 32(3):541-6. PubMed ID: 6221728
[TBL] [Abstract][Full Text] [Related]
13. Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon gamma in renal cell carcinoma cell lines.
Ikemoto S; Sugimura K; Yoshida N; Kuratsukuri K; Wada S; Nakatani T
Anticancer Res; 2002; 22(6C):4023-7. PubMed ID: 12553027
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of metabolites of 1-hexylcarbamoyl-5-fluorouracil and related compounds against L1210 leukemia in vivo and L5178Y lymphoma cells in vitro.
Hoshi A; Yoshida M; Inomata M; Iigo M; Ando N; Kuretani K
J Pharmacobiodyn; 1980 Sep; 3(9):478-81. PubMed ID: 7463306
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
Ait-Tihyaty M; Rachid Z; Mihalcioiu C; Jean-Claude BJ
Breast Cancer Res Treat; 2012 May; 133(1):217-26. PubMed ID: 21915635
[TBL] [Abstract][Full Text] [Related]
16. UFT is more antineoplastic against gastric carcinoma than 5-fluorouracil, 1-(2-tetrahydrofuryl)-5-fluorouracil and 1-hexylcarbamoyl-5-fluorouracil.
Maehara Y; Kusumoto T; Kusumoto H; Anai H; Sugimachi K
Chemotherapy; 1988; 34(6):484-9. PubMed ID: 3149571
[TBL] [Abstract][Full Text] [Related]
17. Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.
Patterson AV; Zhang H; Moghaddam A; Bicknell R; Talbot DC; Stratford IJ; Harris AL
Br J Cancer; 1995 Sep; 72(3):669-75. PubMed ID: 7669579
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic effects of orally administered 5'-deoxy-5-fluorouridine, 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil on experimental murine tumors.
Uehara N; Baba H; Nitta K; Kunimoto T; Takeuchi M; Sasaki T; Tanaka T
Jpn J Cancer Res; 1985 Oct; 76(10):1034-41. PubMed ID: 2934356
[TBL] [Abstract][Full Text] [Related]
19. The antiproliferative effects of fluoropyrimidine derivatives against human tumor xenografts in a subrenal capsule assay.
Nishiyama M; Takagami S; Kirihara Y; Saeki T; Hirabayashi N; Nosoh Y; Niimoto M; Hattori T
Jpn J Surg; 1988 Nov; 18(6):725-8. PubMed ID: 2977626
[TBL] [Abstract][Full Text] [Related]
20. Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma.
Ishikawa T; Tanaka Y; Ishitsuka H; Ohkawa T
Jpn J Cancer Res; 1989 Jun; 80(6):583-91. PubMed ID: 2527217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
